Effectiveness and Safety of Dapagliflozin for Black and White Patients With Chronic Kidney Disease in North and South America-Reference-Cited by-同舟云学术

Effectiveness and Safety of Dapagliflozin for Black and White Patients With Chronic Kidney Disease in North and South America

Published:2023-04-27 Issue:4 Volume:6 Page:e2310877
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Vart Priya¹,Jongs Niels¹,Wheeler David C.²,Heerspink Hiddo J. L.¹³,Langkilde Anna Maria⁴,Chertow Glenn M.⁵⁶

Affiliation:

1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

2. Department of Renal Medicine, University College London, London, United Kingdom

3. The George Institute for Global Health, Sydney, Australia

4. BioPharmaceuticals R&D, AstraZeneca, Gotherburg, Sweden

5. Department of Medicine, Stanford University School of Medicine, Stanford, California

6. Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California

Abstract

This secondary analysis of a randomized clinical trial investigates the relative effectiveness and safety of the sodium-glucose cotransporter-2 inhibitor dapagliflozin for Black and White patients with chronic kidney disease (CKD) in North and South America.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2804230/vart_2023_ld_230064_1683660228.2288.pdf

Reference6 articles.

1. U.S. disparities in health: descriptions, causes, and mechanisms.;Adler;Annu Rev Public Health,2008

2. Racial profiling in medical research.;Schwartz;N Engl J Med,2001

3. White/Black racial differences in risk of end-stage renal disease and death.;Choi;Am J Med,2009

4. Lesser response to angiotensin-converting-enzyme inhibitor therapy in Black as compared with White patients with left ventricular dysfunction.;Exner;N Engl J Med,2001

5. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.;de Zeeuw;Kidney Int,2006

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis;The Lancet Diabetes & Endocrinology;2024-07

2. Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis;Journal of Medical Economics;2023-10-31

3. Rectifying Errors and an Apology for a Study of Possible Differential Effects of an Intervention Among Black and White Patients;JAMA Network Open;2023-05-12

4. Omitted Study Rationale and Acknowledgment of Race as a Social Construct;JAMA Network Open;2023-05-12